In up to 30% of acute myeloid leukemia (AML), chromosomal translocations disrupt one of the core binding factor (CBF) genes most frequently by the t(8;21)(q22;q22). Although patients with CBF leukemia generally have a higher complete remission rate and disease-free survival as compared to those with a normal karyotype or other chromosomal aberrations, additional distinct mutations in genes involved in signal-transduction pathways, particularly in receptor tyrosine kinases (RTKs), herald a higher relapse rate (see below).
The 2-hit hypothesis proposes that most acute leukemias are the consequence of a collaboration of several types of mutations.
1 Class I mutations often affect genes of RTKs, which confer a proliferative and survival advantage to hematopoietic progenitors. Class II mutations are usually chromosomal translocations involving hematopoietic transcription factors, with consecutive impairment of differentiation and apoptosis of cells. Mouse models with high transgene expression of the fusion protein AML1/ETO do not develop leukemia spontaneously. 2 In contrast, specific additional mutational events, for example, FLT3 length mutations, can promote development of leukemia in an AML1/ETO mouse model. 3 There is evidence in cells haploinsufficient for AML1 suggesting a similar cooperative role for the RTK c-kit. 4 The c-kit receptor is encoded by the KIT gene on chromosome 4 (band q11-12) and belongs to the type III RTK family. Binding of stem cell factor, the ligand of c-kit, activates the receptor through dimerization, which facilitates autophosphorylation and intracellular signal transduction (for example, PI3K, JAK-STAT, Ras-Raf-MAPK pathway). Distinct gain-of-function mutations of KIT have been reported to enable ligand-independent activation hyperactivity to SCF binding 8 Letters to the Editor of the c-kit receptor. In AML, KIT mutations are found in exon 8 (encoding the extracellular domain), exon 17 (encoding the second part of the kinase domain) and rarely in other exons, such as exon 10 or 11 (encoding the transmembrane and the juxtamembrane domain, respectively; Figure 1 ). The incidence of KIT mutations in CBF AML varies between 17 and 48%. Notably, patients with t(8;21) AML harboring a mutation in exon 17 (mostly codons 816 or 822) have a much higher cumulative incidence of relapse and a lower overall survival. [5] [6] [7] No significant differences in the incidence of relapse and overall survival were observed in patients with wild-type KIT and mutations other than in exon 17. 6 There are only very few human t(8;21) cell line models, two with constitutive expression of AML1/ETO (Kasumi-1 and SKNO-1) and four with inducible expression of AML1/ETO, all with a U937 background. For Kasumi-1, Beghini et al. 8 identified the KIT mutation N822K and demonstrated that the mutated allele is amplified fivefold. In addition, that mutation leads to a gain-of-function entailing ligand-independent c-kit activation. This raises the question whether KIT is also mutated in SKNO-1 cells. Genomic DNA from SKNO-1, Kasumi-1 and a KIT wild-type melanoma cell culture UFHO-4 was purified. Exons 8, 9, 11, 13 and 17 of KIT were amplified by PCR and directly sequenced (primer sequences available upon request). We identified the identical thymine to adenine mutation resulting in a N822K amino-acid substitution as previously described for Kasumi-1 (Figure 2a) . The mutation was verified by multiple sequencing runs with SKNO-1 DNA of two different sources, followed by RFLP analysis and sequencing after cloning of Kasumi-1 and SKNO-1 KIT exon 17 (Figures 2b and c) .
The absence of wild-type KIT alleles in SKNO-1 was striking and suggested a homozygous mutation. We therefore profiled the genome of SKNO-1 by copy number analysis using Affymetrix 50k XbaI SNP mapping arrays. We found a copy number neutral loss of heterozygosity (LOH) of chromosome 4 in SKNO-1 due to uniparental disomy (UPD) (Figure 3 ). That the entire chromosome is homozygous strongly suggests a nondisjunction event followed by chromosomal duplication. The consequence is the generation of daughter cells exclusively expressing the mutant c-kit receptor. These cells might have a growth advantage, which is underlined by the fact that there is no wild-type KIT detectable in the whole-cell lysate of the SKNO-1 culture. It is noteworthy to mention that SKNO-1 cells are growth factor-dependent (granulocyte-macrophage-colonystimulating factor) while Kasumi-1 are not. Thus, a hypothetical growth advantage might be multicausal and additionally involve other genes affected by the UPD of chromosome 4, such as EIF4E, S100P and CXC-ligands, or by the aberrations of other chromosomes.
Acquired homozygosity in the form of UPD cannot be detected by conventional cytogenetic methods and is described for B20% of AML cases. 9 The distribution of affected chromosomal regions appears nonrandom because some of the regions of UPD include genes known to be mutated in a proportion of AML, such as WT1, FLT3, CEBPA and RUNX1, and may be linked to the clinical outcome. 10 A consequence of UPD could be the unmasking of pre-existing mutations. UPD has also been observed in other clonal hematologic disorders, such as polycythemia vera and childhood acute leukemia, in solid tumors, such as breast cancer and uveal melanoma, and in tumors associated with Beckwith-Wiedemann syndrome. In the general population, UPD is rare.
In conclusion, we identified SKNO-1 as a second c-kit mutant model for t(8;21) AML. Notably, the KIT exon 17 mutation N822K is homozygous in SKNO-1, but not Kasumi-1. The homozygosity in SKNO-1 is caused by the UPD of chromosome 4, which might mediate a growth advantage. To our knowledge, this is the first description of a UPD affecting mutant KIT in AML. It would be of great interest to retrospectively analyze the KIT status of the patients' primary blasts that gave rise to both lines and to determine whether the mutation was acquired in vivo or during cultivation. Even though a small population of blasts bearing such a mutation might be undetectable in the patients by standard analyses, they could nevertheless represent a reservoir for the outgrowth of resistant cells in vivo and in vitro. 
